EE389 Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective ...
Abstract
Authors
Monica M. Rojas Mariana Rosim Victoria Wurcel Felype Castelhano Srushti Gotarkar Gargi Baluni Debosmita Bhadra Abhijoy Kumar Ruixuan Jiang Grant McCarthy